SLC5A2 and type 2 diabetes mellitus: In Japan, the first SGLT2 inhibitor, ipragliflozin, was marketed in 2014, and currently six SGLT2 inhibitors, ipragliflozin, dapagliflozin, canagliflozin, empagliflozin, luseogliflozin, and tofogliflozin, are available for the treatment of type 2 diabetes (T2DM) (Table 1).